Treatments for autoimmune diseases and those in orphan markets are on the up and up, as are drugmakers’ first launches, ...
Amgen (NasdaqGS:AMGN) has recently garnered attention due to promising Phase 3 MINT trial results for UPLIZNA in treating ...
Amgen (NasdaqGS:AMGN)'s recent affirmation of a $2.38 per share dividend for Q2 2025 could reflect investor confidence and ...
The general mood among these heavyweight investors is divided, with 70% leaning bullish and 20% bearish. Among these notable ...
News Medical on MSN11d
Certain genetic alterations may contribute to primary resistance of certain cancers to KRAS G12C inhibitorsThe KRAS G12C mutation is found in approximately 3% of all colorectal cancer cases and 1% to 2% of pancreatic adenocarcinoma ...
Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC. See why I rate CRDF stock as a strong buy.
Two weeks after Amgen reported the top-line result of its CodeBreak-200 trial of Lumakras in lung cancer, the data has been presented in abstract form at ESMO, showing a 34% improvement in ...
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Amgen's whale ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback